

To improve the lives of patients by creating & developing innovative antibody products



2 marketed products

DARZALEX[®] marketed in US, Europe, Japan & other countries
Arzerra[®] marketed in U.S. & Japan



4 proprietary antibody products in clinical development

Tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5, DuoBody-CD3xCD20



~20 pre-clinical projects

Extensive partnered & own pre-clinical pipeline



31 INDs

Investigational new drug applications filed by Genmab & partners since 1999 – Intend to file INDs or CTAs for 3 new products in 2019



4 proprietary technologies

DuoBody[®] platform, HexaBody[®] platform, DuoHexaBody[™] platform & HexElect[™] platform



2 categories of cancer

Generate products to treat both solid tumors & hematological cancers




Solid financial base

Allows for building capabilities to market own product in future

DKK 66B
~USD 10B¹
2018 year end market cap

DKK 3,025M
~USD 464M¹
2018 revenue 28% increase vs 2017

Operating Result MDKK (~MUSD¹)



¹USD 1.00 = DKK 6.5213

DKK 1,645M
~USD 252M¹
2018 operating expenses 87% invested in R&D

DKK 6,106M
~USD 936M¹
2018 year end cash position

2019 Guidance Income Statement

	DKKM	USDM ²
Revenue	4,600	767
Operating expenses	(2,600)	(433)
Operating income	2,000	333

²USD 1.00 = DKK 6.00



Our Three-pronged Strategy

Focus on core competence
Turn science into medicine
Build a profitable & successful biotech



Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
EVP & CFO

Judith Klimovsky M.D.
EVP & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ

Symbol: GEN

ADR ticker Symbol: GMXAY

Stock information
as of March 14, 2019:

Market cap:
~DKK 70 Bn (~USD 10,629 M)

Shares outstanding:
61,523,868

Robust Product Pipeline and Passion for Innovation

Products in Development

Product	Disease Indications	Development Phase				
		Pre-clinical	I	I/II	II	III
Daratumumab Target: CD38, Partner: Janssen	Multiple myeloma (MM) Amyloidosis Non-MM blood cancers					
Ofatumumab (OMB157) Target: CD20, Partner: Novartis	Relapsing multiple sclerosis (RMS) (SubQ)					
Tisotumab vedotin Target: TF, Partner: Seattle Genetics	Cervical cancer Ovarian cancer Solid tumors					
Enapotamab vedotin Target: AXL	Solid tumors					
HexaBody-DR5/DR5 (GEN1029) Target: DR5	Solid tumors					
DuoBody-CD3xCD20 (GEN3013) Targets: CD20, CD3	Hematological malignancies					
Teprotumumab (RV001) Target: IGF-1R, Partner: Horizon Pharma	Graves' orbitopathy					
HuMax-IL8 Target: IL8, Partner: BMS	Advanced cancers					
Camidanlumab tesirine (ADCT-301) Target: CD25, Partner: ADCT	Lymphoma Solid tumors					
JNJ-61186372 Targets: EGFR, cMET, Partner: Janssen	Non-small-cell lung cancer (NSCLC)					
JNJ-63709178 Targets: CD3, CD123, Partner: Janssen	Acute myeloid leukemia (AML)					
JNJ-64007957 Targets: BCMA, CD3, Partner: Janssen	Relapsed or refractory MM					
JNJ-64407564 Targets: CD3, GPRC5D, Partner: Janssen	Relapsed or refractory MM					
Lu AF82422 Target: α-Synuclein, Partner: Lundbeck	Parkinson's Disease					
~20 Active Pre-clinical programs incl., DuoBody-CD40x4-1BB, DuoBody-PD-L1x41BB, DuoHexaBody-CD37	Proprietary programs: DuoBody, HexaBody & DuoHexaBody Partnered programs: HuMab & DuoBody					

Products in development: [Daratumumab](#), [Ofatumumab](#), [Tisotumab vedotin](#), [Enapotamab vedotin](#), [HexaBody-DR5/DR5](#), [DuoBody-CD3xCD20](#), [Pre-clinical programs](#), [Technologies](#)

At-A-Glance – SELECTED PRODUCTS

DARZALEX® (daratumumab)³

- First-in-class CD38 antibody in dev. to treat cancer
- Approved in combo. w/ other therapies for frontline MM in US & EU; in combo. w/ other therapies in RRMM in US, EU & Japan; as monotherapy for heavily pretreated or double refractory MM in US & EU. Split dose of 1st infusion approved in US & EU
- Multiple Ph., III studies ongoing in MM, amyloidosis & SC formulation
- Early stage studies in other blood cancers
- Collaboration w/ Janssen
- 2018 net sales by Janssen: \$2,025M

Tisotumab vedotin

- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in dev. to treat solid tumors
- Ph. II potential registration study in cervical cancer ongoing; Ph. II clinical studies in ovarian, colorectal, pancreatic and NSCLC, and squamous cell carcinoma of the head and neck announced or ongoing
- License & collaboration agreement w/ Seattle Genetics

Enapotamab vedotin

- ADC in development to treat solid tumors
- Ph I/II clinical study for solid tumors ongoing, incl., expansion cohorts in NSCLC, melanoma & sarcoma

Arzerra® (ofatumumab)³

- Human CD20 monoclonal antibody developed in collaboration w/ Novartis
- Approved in certain territories for various CLL indications
- 2018 net sales by Novartis: \$26M

Ofatumumab (OMB157)

- SC formulation in development to treat RMS
- Recruitment completed in 2 Ph. III studies in RMS

HexaBody-DR5/DR5

- Proprietary antibody therapeutic created w/ Genmab's HexaBody technology
- Composed of two non-competing HexaBody molecules that target two distinct DR5 epitopes
- Phase I/II clinical trial in solid tumors started

DuoBody-CD3xCD20

- Proprietary bispecific antibody created w/ Genmab's DuoBody technology
- Phase I/II clinical trial in B-cell malignancies ongoing

³See local country prescribing information for precise indications

TECHNOLOGIES

DuoBody® Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

DuoHexaBody™ Platform

- Antibody technology that combines DuoBody & HexaBody platform
- Creates bispecific antibodies w/ target-mediated enhanced potency

HexaBody® Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology
- First HexaBody product in development – HexaBody-DR5/DR5

HexElect™ Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting w/ enhanced selectivity & potency